Advertisement
BEAM vs EDIT
Which Stock Would AI Choose? Beam Therapeutics (BEAM) vs. Editas Medicine (EDIT) Stock Comparison
Key Takeaways
- Different gene-editing technologies: Beam Therapeutics (BEAM) uses base editing, while Editas Medicine (EDIT) uses CRISPR/Cas9 and Cas12 systems.
- Pipeline stage gap: BEAM has multiple clinical-stage programs nearing regulatory filings, while EDIT is pivoting around an early-stage in vivo candidate.
- Balance sheet contrast: BEAM holds roughly $1.2 billion in cash versus about $212 million for EDIT.
- Momentum divergence: EDIT has shown stronger year-to-date gains, but BEAM carries a larger market value and broader pipeline.
- Risk profiles differ: Both remain pre-revenue, clinical-stage biotechs exposed to binary clinical and regulatory outcomes.
- For more context on each company's headlines and daily price action, explore the BEAM Major News, BEAM Today's Price Move, EDIT Major News, and EDIT Today's Price Move pages.
- For automated, data-driven trading ideas across this sector and beyond, explore the curated Trending AI Robots.
Introduction
Beam Therapeutics and Editas Medicine are two clinical-stage biotechnology companies competing at the frontier of genetic medicine, yet they approach the same goal with different tools. Beam has built its platform around base editing, which rewrites single DNA "letters" without cutting the DNA strand, while Editas leverages the better-known CRISPR/Cas9 and Cas12 systems. Both remain pre-revenue and unprofitable, making their share prices highly sensitive to clinical data, regulatory milestones, and cash runway. For growth-oriented and biotech-specialist investors weighing relative performance, market positioning, and pipeline risk, this stock comparison offers a useful framework for understanding how two prominent gene-editing names stack up in the current market environment.
BEAM Overview and Recent Performance
BEAM is a Cambridge, Massachusetts-based biotechnology company focused on base editing, a precision approach often described as a "molecular pencil" that chemically corrects a single base pair without creating double-stranded DNA breaks. Its lead programs include risto-cel for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency (AATD), and earlier-stage candidates for glycogen storage disease and phenylketonuria.
In recent market activity, the stock has traded in a choppy range. Shares rose sharply after a strong quarterly update earlier in the year but retreated in recent weeks after updated BEAM-302 trial data was described by analysts as solid yet not numerically improved from prior readouts. The company has secured FDA (U.S. Food and Drug Administration) alignment on an accelerated approval pathway for BEAM-302 and has guided toward a biologics license application for risto-cel, creating nearer-term catalysts. With roughly $1.2 billion in cash and a runway projected into mid-2029, BEAM carries one of the stronger balance sheets among gene-editing peers.
EDIT Overview and Recent Performance
EDIT is a Cambridge, Massachusetts-based genome-editing company built around CRISPR/Cas9 and Cas12 technology. After discontinuing its reni-cel program and restructuring operations, the company has refocused on EDIT-401, an in vivo (inside-the-body) gene-editing candidate targeting the LDLR gene for heterozygous familial hypercholesterolemia, an inherited cholesterol disorder.
In recent weeks, EDIT has generated notable momentum. The company reported narrowing losses and higher collaboration revenue, presented encouraging preclinical data showing durable LDL (low-density lipoprotein, or "bad" cholesterol) reductions in non-human primates, and received clearance to initiate a Phase 1/2 clinical trial in Australia. Shares have climbed substantially year-to-date, though the stock remains in the low single digits with a market capitalization well below its larger peer. With about $212 million in cash expected to fund operations into the second half of 2028, funding and execution risk remain central considerations for investors.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies designed to adapt to shifting market conditions. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, but only those judged most suitable for the current environment earn a place in this featured section. These bots span varied trading styles, strategies, timeframes, performance statistics, and underlying ticker sets, offering traders a range of approaches from short-term momentum to longer-horizon positioning. Because the selection is refreshed to reflect live market dynamics, the page serves as a practical starting point for investors interested in systematic, data-driven trading. Explore the Trending AI Robots to review currently featured strategies.
Head-to-Head Comparison
Although both companies operate in gene editing, their business models and risk profiles diverge in several ways. BEAM has a broader, more advanced pipeline with multiple clinical programs and clearer near-term regulatory paths, supported by a substantially larger cash balance. EDIT is leaner and more concentrated, effectively betting on a single early-stage candidate in a large cardiovascular market.
On growth drivers, BEAM is positioned around near-term data readouts and potential filings, while EDIT is driven by preclinical-to-clinical translation and early human data. In terms of recent momentum, EDIT has delivered stronger percentage gains over the past year, though from a much lower base, while BEAM has been steadier but recently pressured by a mixed data update. Both carry elevated beta and short interest, reflecting high investor debate. Sector exposure is similar, but EDIT's smaller capital base makes it more sensitive to dilution and financing conditions.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, and catalyst density, Tickeron's AI would likely express a relative preference for BEAM at present. The company's deeper cash runway, multiple advanced clinical programs, and nearer-term regulatory milestones provide a more diversified and stable setup than a single, early-stage lead asset. That said, EDIT offers a higher-risk, potentially higher-reward profile given its stronger recent momentum and concentrated upside tied to EDIT-401. Any verdict should be viewed as probabilistic rather than definitive, as both names remain exposed to binary clinical outcomes and shifting biotech sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and EDIT is a Hold.
BEAM in upward trend: 10-day moving average broke above 50-day moving average on November 03, 2026
The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 68 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +4.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for BEAM moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 56 cases where BEAM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
BEAM moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
BEAM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.555) is normal, around the industry mean (3.498). P/E Ratio (-38.275) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BEAM | EDIT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 99 | |
PRICE GROWTH RATING 1..100 | 50 | 58 | |
P/E GROWTH RATING 1..100 | 45 | 30 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BEAM's Valuation (5) in the null industry is somewhat better than the same rating for EDIT (53) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than EDIT’s over the last 12 months.
BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to EDIT’s over the last 12 months.
BEAM's SMR Rating (92) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that BEAM’s stock grew similarly to EDIT’s over the last 12 months.
BEAM's Price Growth Rating (50) in the null industry is in the same range as EDIT (58) in the Biotechnology industry. This means that BEAM’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (30) in the Biotechnology industry is in the same range as BEAM (45) in the null industry. This means that EDIT’s stock grew similarly to BEAM’s over the last 12 months.
| BEAM | EDIT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 89% |
| Advances ODDS (%) | 3 days ago 76% | 3 days ago 80% |
| Declines ODDS (%) | 10 days ago 84% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| Aroon ODDS (%) | N/A | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).
- BEAM’s FA Score: 1 green, 4 red.
- EDIT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 3 TA indicator(s) are bullish while EDIT’s TA Score has 2 bullish TA indicator(s).
- BEAM’s TA Score: 3 bullish, 5 bearish.
- EDIT’s TA Score: 2 bullish, 7 bearish.
Price Growth
BEAM (@Biotechnology) experienced а -4.48% price change this week, while EDIT (@Biotechnology) price change was -3.65% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.16%. For the same industry, the average monthly price growth was -2.54%, and the average quarterly price growth was -13.20%.
Reported Earning Dates
BEAM is expected to report earnings on Mar 02, 2027.
EDIT is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+5.16% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| LIT.X | 3.464561 | 0.236335 | +7.32% |
| Lighter cryptocurrency | |||
| ALPINE.X | 0.283738 | -0.002453 | -0.86% |
| Alpine F1 Team Fan Token cryptocurrency | |||
| WIN.X | 0.000065 | -0.000001 | -1.64% |
| WINkLink cryptocurrency | |||
| AUCTION.X | 2.874088 | -0.082668 | -2.80% |
| Bounce Token cryptocurrency | |||
| FOR.X | 0.000042 | -0.001353 | -96.99% |
| ForTube cryptocurrency | |||